Loading…
← CockpitCompetitor Analysis › 2493.HK Mabwell (Shanghai) Bioscience Co., Ltd. Class HOpen in the cockpit ↗

Mabwell (Shanghai) Bioscience Co., Ltd. Class H2493.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

Chinese biotech developing antibody and antibody-drug-conjugate (ADC) therapies for cancer.

≈ A Chinese ADC-focused biotech, akin to a smaller SeagenMomentum weak 36
Mkt cap
$1.20B
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$364,061
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-30.5 pp
WACC 5.4%
Hurdle
n/a
no reverse DCF
Close · HKDHK$17.67
1D-0.7%
1W-2.7%
1M-8.0%
3M-16.0%
6M-29.1%
YTDn/a
1Yn/a
ATR %5.3%
52w lowhigh43.8% off high

What Mabwell (Shanghai) Bioscience does

Chinese biotech developing antibody and antibody-drug-conjugate (ADC) therapies for cancer.

In one line: A Chinese ADC-focused biotech, akin to a smaller Seagen.

Products and services

  • ADC oncology pipeline
  • Monoclonal antibody pipeline

Customers

  • Hospitals/oncologists in China
  • Global pharma licensing partners

Where it sits in the supply chain

  • Biotechnology
  • Antibody & ADC therapeutics
  • Oncology drugs

What could go right

  • Global ADC licensing deals

What could go wrong

  • Clinical trial risk
  • Pre-revenue cash burn

Moat: narrow (IP / patents, process know-how). Proprietary ADC linker/payload technology platform.

Headquarters: Shanghai, China · Founded: 2017 · Employees: 1,325

Named competitors

Mabwell (Shanghai) Bioscience at a glance

Size Mabwell (Shanghai) Bioscience (2493.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $1.20B, the 532nd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$17.67 on 18 Nov 2026.

Performance Over six months the shares fell 29.1%, against -17.3% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue grew 20.9% over the last twelve months (peer median +3.1%); the operating margin is -126.8% (peer median 0.8%).

Valuation It trades at 13.6× enterprise value to sales against a peer median of 7.6× (4th most expensive of 18).

Capital Return on invested capital runs 30.5 points below its cost of capital (5.4% WACC).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 852493.HK 73
Six months, rebased to 100: Mabwell (Shanghai) Bioscience against the median of its 20 peers (local-currency closes).

Mabwell (Shanghai) Bioscience financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$822MHK$717MHK$215MHK$140MHK$32.2M
Revenue growth—+233%+54%+334%—
Gross profitHK$681MHK$419MHK$42.9MHK$17.5M-HK$79.3M
EBITDAn/a-HK$729M-HK$959M-HK$1.08B-HK$1.05B
Net income-HK$1.19B-HK$1.05B-HK$1.13B-HK$1.16B-HK$1.11B
Free cash flow-HK$1.19B-HK$484M-HK$1.39B-HK$1.41B-HK$1.47B
Capital expenditureHK$123MHK$171MHK$358MHK$552MHK$634M
Total debtHK$4.32BHK$3.31BHK$2.36BHK$1.42BHK$870M

Quarterly statements and history in the cockpit →

Mabwell (Shanghai) Bioscience competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%3000062616HROW688321347850688443NKTR6855IDIA300026AVLN000989GPCR000950GHRS4547002550AMPH2493.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Mabwell (Shanghai) Bioscience is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%+200%0×250×500×750×3000062616HROW347850688443NKTR68552493.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Mabwell (Shanghai) Bioscience is the large dot.

Mabwell (Shanghai) Bioscience competitors and peer comparison

Head to head with its named competitors (2493.HK vs PFE vs 9995.HK vs 1801.HK)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Mabwell (Shanghai) Bioscience 2493.HK$1.20B-29%+21%-127%13.6×n/a
Pfizer PFE$160B+9%+1%26%3.3×-4.3%
RemeGen 9995.HK$6.07B-28%+293%61%4.4×-6.8%
Innovent Biologics 1801.HK$18.9B+4%+43%17%7.3×11.6%

How Mabwell (Shanghai) Bioscience compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Mabwell (Shanghai) Bioscience against its 20 peers (data as of 18 Nov 2026)
Measure2493.HKPeer medianRank in peer set
1-month return-8.0%-5.1%8th lowest of 21
6-month return-29.1%-17.3%7th lowest of 21
Distance from 52-week high-43.8%-39.3%8th lowest of 21
Revenue growth (TTM)+20.9%+3.1%7th highest of 18
Operating margin-126.8%0.8%4th lowest of 18
EV / Sales13.6×7.6×4th most expensive of 18
ROIC minus cost of capital-30.5 pp-5.1 pp5th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Mabwell (Shanghai) Bioscience 2493.HKHong Kong$1.20B-29%+21%-127%13.6×n/an/a
Chongqing Lummy Pharmaceutical 300006.SZChina$1.21B+26%-6%-19%10.4×44.1%-13.2%
CStone Pharmaceuticals 2616.HKHong Kong$1.21B-22%+117%-89%17.0×n/an/a
Harrow HROWUnited States$1.21B+4%+21%1%4.7×n/an/a
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%7.6×n/an/a
D&D Pharmatech 347850.KSSouth Korea$1.22B-49%-77%-2,324%818.8×n/an/a
Chongqing Genrix Biopharmaceutical 688443.SSChina$1.18B-22%+256%-27%8.6×n/an/a
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%13.3×n/an/a
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%13.2×n/an/a
Idorsia IDIA.SWSwitzerland$1.22B-9%-5%-70%10.4×n/an/a
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%1.8×7.0%-5.3%
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%2.6×-4.0%-9.0%
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%0.5×n/an/a
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%4.8×3.4%+27.9%
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%39.1×n/an/a
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%1.4×n/an/a
Changzhou Qianhong Bio-Pharma 002550.SZChina$1.14B-12%-2%15%4.2×3.4%-1.2%
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%2.3×2.5%+15.5%

Questions

Who are Mabwell (Shanghai) Bioscience's main competitors?
Named competitors: Seagen (Pfizer) (PFE), RemeGen (9995.HK), Innovent Biologics (1801.HK). The cockpit's measured peer set (industry) also includes Chongqing Lummy Pharmaceutical (300006.SZ), CStone Pharmaceuticals (2616.HK), Harrow (HROW), Shenzhen Chipscreen Biosciences (688321.SS), D&D Pharmatech (347850.KS), Chongqing Genrix Biopharmaceutical (688443.SS).
Is Mabwell (Shanghai) Bioscience expensive compared with its peers?
On ev / sales it trades at 13.6× against a peer median of 7.6×, 4th most expensive of 18 in its peer set.
How has Mabwell (Shanghai) Bioscience stock performed?
Over six months to 18 Nov 2026 the shares returned -29.1% against -17.3% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.